• Sunshine Biopharma closed a public offering issuing 10,909,082 Common Units or Pre-Funded Units, each with two Series D Warrants.
• Series D Warrants are immediately exercisable at an initial exercise price of $0.66, expiring five years from issuance.
• Warrant exercise could generate about $14.4 million in additional gross proceeds, on top of about $6 million upfront.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sunshine Biopharma Inc. published the original content used to generate this news brief on October 09, 2026, and is solely responsible for the information contained therein.